Abbott Laboratories (ABT) intrinsic value & 10-year financials
Abbott Laboratories (ABT) has a Graham intrinsic value of $123.56 per share. At $104.89 on Oct 17, 2026, the stock trades 15% below that value. Over the last 10 fiscal years revenue grew 8.7% a year to $44.3B, with an average return on invested capital of 10.8%.
- Graham intrinsic value
- $123.56
- Share price (Oct 17, 2026)
- $104.89
- Price vs Graham value
- 15% below
- Market cap
- $183.3B
- Revenue (FY2025)
- $44.3B
- Revenue growth (10-yr CAGR)
- 8.7%
- ROIC (10-yr avg)
- 10.8%
- Free cash flow (FY2025)
- $7.4B
ABT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $44.3B | $6.5B | $3.72 | $7.4B | 18.2% | 11.0% |
| FY2024 | $42.0B | $13.4B | $7.64 | $6.4B | 16.3% | 13.3% |
| FY2023 | $40.1B | $5.7B | $3.26 | $5.1B | 16.2% | 12.1% |
| FY2022 | $43.7B | $6.9B | $3.91 | $7.8B | 19.2% | 15.6% |
| FY2021 | $43.1B | $7.1B | $3.94 | $8.6B | 19.6% | 16.1% |
| FY2020 | $34.6B | $4.5B | $2.50 | $5.7B | 15.5% | 10.6% |
| FY2019 | $31.9B | $3.7B | $2.06 | $4.5B | 14.2% | 8.9% |
| FY2018 | $30.6B | $2.4B | $1.33 | $4.9B | 11.9% | 6.2% |
| FY2017 | $27.4B | $477.0M | $0.27 | $4.4B | 6.3% | 2.4% |
| FY2016 | $20.9B | $1.4B | $0.94 | $2.1B | 15.3% | 11.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Abbott Laboratories is a consistent compounder, expanding top-line revenue at 8.7% annually over the past decade.
Abbott Laboratories returns on capital have been average, hovering around 10.8% ROIC over the decade.
Over the decade, Abbott Laboratories shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Abbott Laboratories is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $123.56 per share.